After the later treatment period (tumor progression), in which no difference in tumor area and proliferation rate had been observed, the difference in Bcl-2 positivity between treatment groups was also not persisting (Fig. 5d; see Bcl-2 staining of the total pancreas in Supplementary Fig. S10B). The gene discussed is BCL2; the disease is neoplasm.